Avanos Medical stock moves draw attention after recent performance

Avanos Medical (AVNS) has come onto investors’ radar as the stock’s recent performance contrasts with its mixed longer term record. This has prompted a closer look at how its current valuation lines up with fundamentals.

The recent surge stands out, with Avanos Medical posting a 1 month share price return of 80.94% and a year to date share price return of 121.56%. However, the 5 year total shareholder return of a 36.03% loss shows the longer term picture is still catching up to the latest momentum.

If this kind of sharp move has your attention, it can be useful to see what else is moving in related areas and compare with 35 healthcare AI stocks

With Avanos Medical now valued at about US$1.16b on roughly US$715.9m of revenue and a recent net loss of US$74.4m, you have to ask: is this a genuine mispricing, or is the market already banking on future growth?

Price-to-Sales of 1.6x: Is it justified?

On roughly $715.9m of revenue and a market value around $1.16b, Avanos Medical currently trades on a P/S of 1.6x, compared with peers and the wider Medical Equipment industry at higher levels.

P/S compares the company’s market value to its annual revenue. This can be useful when earnings are negative, as they are here with a net loss of $74.4m. For a business selling medical devices into hospitals and healthcare providers, investors often look at this ratio to gauge how much the market is paying for each dollar of sales when profit trends are still developing.

In this case, Avanos Medical’s 1.6x P/S sits below both the US Medical Equipment industry average of 2.8x and the peer group average of 4.6x. This indicates the stock trades at a lower revenue multiple than many comparable companies. However, when lined up against the estimated fair P/S of 1.2x, that same 1.6x starts to look richer. This suggests there is room for the valuation to move closer to that lower fair ratio level if sentiment cools.

Result: Price-to-Sales of 1.6x (ABOUT RIGHT)

However, the recent excitement still sits alongside a US$74.4m net loss and a 36.03% 5 year total return decline, which could quickly cool sentiment.

Next Steps

The stock’s sharp recent move and mixed longer term record may leave you torn, so it makes sense to act quickly and test the numbers yourself. To see what is worrying some investors, start by reviewing the 2 important warning signs

Looking for more investment ideas?

If Avanos Medical has caught your eye, do not stop there. Cast the net wider and compare it with other stocks that might better match your goals.

• Target potential bargains by scanning 51 high quality undervalued stocks to see which companies currently look cheap relative to their fundamentals.
• Prioritise resilience by reviewing 71 resilient stocks with low risk scores, focusing on companies that score well on stability and risk metrics.
• Spot overlooked opportunities by checking screener containing 23 high quality undiscovered gems, which highlights businesses that combine strong fundamentals with relatively low attention from the market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.